Beta Bionics, Inc. BBNX

Competitive advantage analysis · healthcare

Medical Devices & Diagnostics
Overall moat score
46/100
Developing

About Beta Bionics, Inc.

Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also … Full BBNX analysis →

Competitive advantage assessment

Key strengths

  • Improving FCF Trend FCF trend score is positive (score 0.90). Improving FCF margin signals compounding operational leverage.
  • Expanding Operating Margin Operating margin trend is positive (score 0.91). Margin expansion confirms commercial leverage is building.

Key risks

  • Weak Capital Return Profile Capital return quality is below peers (score 0.29). Low ROIC raises questions about M&A discipline and pipeline ROI.
  • Weak FCF Generation FCF margin quality lags peers (score 0.39). Below-peer FCF conversion is a MedTech quality warning.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power & Consumable Moat

Developing
33

Where BBNX ranks in Medical Devices

Beta Bionics, Inc. ranks #89 of 160 scored companies in Medical Devices by moat score — the top 56%. The widest moat in the group is iRadimed Corporation (IRMD) at 83/100.

Moat scores for companies ranked near BBNX in Medical Devices
# Company Moat score Rating
85 NeuroOne Medical Technologies C NMTC 48/100 Developing
86 Strata Skin Sciences, Inc. SSKN 47/100 Developing
87 Integra LifeSciences Holdings C IART 46/100 Developing
88 Sensus Healthcare, Inc. SRTS 46/100 Developing
89 Beta Bionics, Inc. BBNX 46/100 Developing
90 Pheton Holdings Ltd PTHL 45/100 Developing
91 IRIDEX Corporation IRIX 45/100 Developing
92 Catheter Precision, Inc. VTAK 44/100 Developing
93 MaxCyte, Inc. MXCT 44/100 Developing

See every Medical Devices & Diagnostics company ranked by moat score →

How BBNX scores on the Medical Devices & Diagnostics defenses

Pricing Power & Consumable Moat

Score 33 · 25% of the moat score

In MedTech, pricing power is rarely about the machine — it is about what the machine consumes.

R&D Pipeline & Capital Returns

Score 35 · 20% of the moat score

Research spending is how a device company keeps its installed base current, but spending alone proves nothing.

FCF Quality & Cash Conversion

Score 62 · 20% of the moat score

MedTech companies grow by acquisition, and the resulting intangible amortisation depresses reported earnings without consuming any cash.

Commercial Execution

Score 60 · 15% of the moat score

Devices are sold into hospitals and labs through committees, tenders and long qualification cycles, which makes the sales organisation expensive and hard to replicate.

Capital Structure & Resilience

Score 75 · 12% of the moat score

Serial acquirers carry debt, and the question is whether the cash flows underneath it are dependable enough to service it through a downturn.

Growth Durability

Score 21 · 8% of the moat score

Growth durability separates an expanding installed base from a good product cycle.

How each Medical Devices & Diagnostics defense is measured, in full →

Understanding BBNX's moat

What is Beta Bionics, Inc.'s moat score?

Beta Bionics, Inc. (BBNX) scores 46 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #89 of 160 scored companies in Medical Devices, the top 56%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 159 companies in Medical Devices. Its strongest defense is Capital Structure & Resilience (75/100) and its weakest is Growth Durability (21/100).

How does Beta Bionics, Inc. compare with other Medical Devices companies?

Beta Bionics, Inc. ranks #89 of 160 scored companies in Medical Devices by moat score. The widest moat in Medical Devices is iRadimed Corporation (IRMD) at 83/100. The companies ranked closest are Sensus Healthcare, Inc. (SRTS) at 46 just above it and Pheton Holdings Ltd (PTHL) at 45 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Medical Devices & Diagnostics in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 159 companies in Medical Devices. The defenses are then weighted to produce the overall score out of 100.

Why is Beta Bionics, Inc. scored with the Medical Devices & Diagnostics template?

Medical device and diagnostics companies place an instrument once and then sell the consumables, reagents and service that instrument needs for the next decade. The economics are a razor-and-blade model wrapped in regulatory approval and clinician habit, so the MedTech template scores the durability of that installed base rather than the size of any single product launch.

Which competitive defenses are measured for Beta Bionics, Inc.?

The Medical Devices & Diagnostics template measures 6 defenses, and BBNX scores: Pricing Power & Consumable Moat (33), R&D Pipeline & Capital Returns (35), FCF Quality & Cash Conversion (62), Commercial Execution (60), Capital Structure & Resilience (75), Growth Durability (21). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000